Acelrx Pharmaceuticals Inc Price/Book
Cos'è Price/Book di Acelrx Pharmaceuticals Inc?
Price/Book di Acelrx Pharmaceuticals Inc è 13.18
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su NASDAQ rispetto a Acelrx Pharmaceuticals Inc
Cosa fa Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Aziende con price/book simili a Acelrx Pharmaceuticals Inc
- Newgen Software Technologies ha Price/Book di 13.14
- POCL Enterprises ha Price/Book di 13.16
- Magna Mining Inc ha Price/Book di 13.17
- Kirloskar Ferrous Industries ha Price/Book di 13.17
- NGL Fine-Chem ha Price/Book di 13.17
- Thangamayil Jewellery ha Price/Book di 13.17
- Acelrx Pharmaceuticals Inc ha Price/Book di 13.18
- Quartz Mountain Resources ha Price/Book di 13.19
- Atlas Copco AB ha Price/Book di 13.19
- Gufic Biosciences ha Price/Book di 13.20
- Wave Life Sciences ha Price/Book di 13.20
- MongoDB Inc ha Price/Book di 13.20
- Amber Enterprises India ha Price/Book di 13.20